Canadian Emergency Department Opioid Registry (CEDRN)
Official title: Optimizing Outcomes for Patients Presenting to Emergency Departments With Opioid Poisoning
Run by University of British Columbia · NCT07466784 · Data updated 2026-11-12
This project will create a national emergency department registry to collect information on people of all ages who come to EDs with suspected or confirmed opioid poisoning to see if those data can guide better care and prevent deaths.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 7200 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Vancouver, British Columbia) |
| Status | Recruiting |
| Started | July 24, 2025 |
| Main results expected | July 24, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT07466784 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People of any age who present to a participating Canadian emergency department with suspected or confirmed opioid poisoning, opioid withdrawal, or related opioid-use diagnoses, or who have opioid-related medications or naloxone recorded in recent visits, are the intended participants.
✕Probably not a fit
People who do not present to participating EDs, those with only non-opioid overdoses, or individuals treated entirely outside hospital settings are unlikely to receive direct benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The CEDRN Opioid Registry will use automated screening of electronic health records at participating emergency departments to identify consecutive patients with suspected or confirmed opioid poisoning, opioid withdrawal, or related diagnoses. Sites will harmonize data collection on patient demographics, presentation details, ED and in-hospital treatments (including naloxone and opioid agonist therapies), and short-term clinical outcomes. Data will be aggregated across participating Canadian EDs to characterize care patterns, gaps, and outcomes and to enable timely, practice-informing analyses. The registry is observational and does not change individual patient care but aims to generate high-quality evidence to improve ED responses to the unregulated drug crisis.
Why it matters
Potential benefit: If successful, the registry could identify effective ED practices and gaps, helping to speed adoption of life-saving treatments and improve links to harm reduction and addiction care to reduce opioid-related deaths.
How similar studies have gone: Regional ED and overdose surveillance systems have provided useful public-health insights, but a harmonized pan-Canadian emergency-department opioid registry at this scale is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients who arrive at the emergency department with the following emergency department discharge diagnosis: * Percocet Overdose * Oxycontin Overdose * Oxycodone Overdose * Opioid Overdose or Intoxication * Methadone Overdose * Heroin Overdose * Fentanyl Overdose * Codeine Overdose * Carfentanil Overdose * Opioid Withdrawal 2. All patients who arrive at the emergency department who had the following medication ordered in the present visit or previous hospital visits in the past 2 years: * Buprenorphine * Buprenorphine-naloxone * Methadone - Past ED or IP encounter * Kadian/Morphine long-acting * Naloxone * Naloxone kit 3. All patients who arrive at the emergency department with the following impatient discharge diagnosis: * Opioid use disorder (mild/moderate/severe, abuse/dependence), or opioid-related disorders * Adverse effect, and poisoning by polysubstance use * Opioid intoxication or withdrawal * Intoxication or withdrawal (from any substance, including unspecified ones) * Adverse effect, and poisoning by opioids, benzodiazepines, other antiepileptic and sedative-hypnotic drugs, and unspecified drugs * Any psychoactive substance abuse resulting in intoxication, withdrawal, or any adverse effects
Where it's running
-
Vancouver General Hospital
Vancouver, British Columbia, Canada Recruiting
Study contacts
- Principal investigator: Corinne M Hohl, MD, MPH — University of British Columbia
- Study coordinator: Jeffrey P Hau, MSc
- Email: jeffrey.hau@ubc.ca
- Phone: 16048754111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Measuring physiological symptoms during opioid withdrawal and cravings
This study is testing how the body reacts during opioid withdrawal and cravings in people with opioid dependence by using smartwatches to track their heart rate, skin temperature, and other signals over two weeks.
-
Using buspirone to help with opioid withdrawal
This study is testing if the medication buspirone can help people with opioid use disorder feel less withdrawal symptoms and cravings while they are tapering off opioids.
-
Evaluating opioid withdrawal symptoms during medication tapering
This study is testing how different people experience withdrawal symptoms when they slowly reduce their opioid use under medical supervision to help improve treatment for opioid use disorder.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.